Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference
Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, announced that CEO Jill C. Milne, Ph.D. will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference.
The presentation is scheduled for Tuesday, March 4th at 9:50am ET in Boston, MA. Interested parties can access a webcast of the presentation through a provided link, and an archived replay will remain available in the investors section of the company's website for 30 days following the event.
This conference appearance represents an opportunity for Astria to share updates on their development of life-changing therapies with healthcare industry stakeholders and potential investors.
Astria Therapeutics (Nasdaq: ATXS), una società biofarmaceutica che sviluppa terapie per malattie allergiche e immunologiche, ha annunciato che il CEO Jill C. Milne, Ph.D. parteciperà a una chiacchierata informale al 45° Congresso Annuale sulla Salute di TD Cowen.
La presentazione è programmata per martedì 4 marzo alle 9:50 ET a Boston, MA. Le parti interessate possono accedere a un webcast della presentazione tramite un link fornito, e una registrazione archiviata rimarrà disponibile nella sezione investitori del sito web dell'azienda per 30 giorni dopo l'evento.
Questa partecipazione alla conferenza rappresenta un'opportunità per Astria di condividere aggiornamenti sullo sviluppo di terapie che cambiano la vita con i portatori di interesse del settore sanitario e potenziali investitori.
Astria Therapeutics (Nasdaq: ATXS), una compañía biofarmacéutica que desarrolla terapias para enfermedades alérgicas e inmunológicas, anunció que la CEO Jill C. Milne, Ph.D. participará en una charla informal en la 45ª Conferencia Anual de Salud de TD Cowen.
La presentación está programada para el martes 4 de marzo a las 9:50 a.m. ET en Boston, MA. Las partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de un enlace proporcionado, y una repetición archivada estará disponible en la sección de inversores del sitio web de la compañía durante 30 días después del evento.
Esta aparición en la conferencia representa una oportunidad para que Astria comparta actualizaciones sobre el desarrollo de terapias que cambian vidas con los interesados en la industria de la salud y posibles inversores.
Astria Therapeutics (Nasdaq: ATXS), 알레르기 및 면역 질환 치료제를 개발하는 생명공학 회사는 CEO Jill C. Milne, Ph.D.가 TD Cowen 제45회 연례 건강 관리 회의에서 대담에 참여할 것이라고 발표했습니다.
발표는 3월 4일 화요일 오전 9시 50분 ET에 매사추세츠주 보스턴에서 예정되어 있습니다. 관심 있는 분들은 제공된 링크를 통해 발표의 웹캐스트에 접속할 수 있으며, 이벤트 후 30일 동안 회사 웹사이트의 투자자 섹션에서 아카이브된 재생이 제공됩니다.
이번 컨퍼런스 참석은 Astria가 의료 산업 이해관계자 및 잠재적 투자자와 함께 삶을 변화시키는 치료 개발에 대한 업데이트를 공유할 수 있는 기회를 제공합니다.
Astria Therapeutics (Nasdaq: ATXS), une entreprise biopharmaceutique développant des thérapies pour les maladies allergiques et immunologiques, a annoncé que la PDG Jill C. Milne, Ph.D. participera à une discussion informelle lors de la 45e Conférence Annuelle sur la Santé de TD Cowen.
La présentation est prévue pour mardi 4 mars à 9h50 ET à Boston, MA. Les parties intéressées peuvent accéder à un webinaire de la présentation via un lien fourni, et un replay archivé sera disponible dans la section investisseurs du site web de l'entreprise pendant 30 jours après l'événement.
Cette apparition à la conférence représente une opportunité pour Astria de partager des mises à jour sur le développement de thérapies qui changent la vie avec les parties prenantes de l'industrie de la santé et les investisseurs potentiels.
Astria Therapeutics (Nasdaq: ATXS), ein biopharmazeutisches Unternehmen, das Therapien für allergische und immunologische Erkrankungen entwickelt, gab bekannt, dass CEO Jill C. Milne, Ph.D. an einem informellen Gespräch auf der 45. jährlichen Gesundheitskonferenz von TD Cowen teilnehmen wird.
Die Präsentation ist für Dienstag, den 4. März um 9:50 Uhr ET in Boston, MA, geplant. Interessierte Parteien können über einen bereitgestellten Link auf einen Webcast der Präsentation zugreifen, und eine archivierte Wiederholung wird 30 Tage nach der Veranstaltung im Investorenbereich der Unternehmenswebsite verfügbar sein.
Diese Teilnahme an der Konferenz bietet Astria die Möglichkeit, Updates zu ihren Entwicklungen lebensverändernder Therapien mit Akteuren der Gesundheitsbranche und potenziellen Investoren zu teilen.
- Astria Therapeutics' participation in a major healthcare conference increases visibility with investors and industry experts
- The company's CEO personally presenting suggests confidence in their development pipeline
- Providing webcast access demonstrates transparency and commitment to shareholder communication
- The press release doesn't provide specific updates on the company's drug development progress
- No financial information or business updates are included in the announcement
- The announcement is purely about conference participation rather than substantive business developments
A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/cowen177/atxs/2050656. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225377705/en/
Astria:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
When is Astria Therapeutics (ATXS) presenting at the TD Cowen Health Care Conference?
How can investors watch Astria Therapeutics' (ATXS) presentation at the TD Cowen conference?
What therapeutic areas does Astria Therapeutics (ATXS) focus on developing treatments for?
Who will represent Astria Therapeutics (ATXS) at the TD Cowen Health Care Conference?
What type of presentation will Astria Therapeutics (ATXS) deliver at the TD Cowen conference?
